Paroxysmal Nocturnal Hemoglobinuria（PNH） - Medical Tourism & Treatment Guide in China

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis, bone marrow failure, and thrombophilia. It arises from somatic mutations in the *PIGA* gene, leading to deficient expression of glycosylphosphatidylinositol (GPI)-anchored proteins—particularly CD55 and CD59—on blood cell membranes. This deficiency renders erythrocytes susceptible to uncontrolled complement activation, resulting in chronic hemolysis, fatigue, dyspnea, abdominal pain, and an elevated risk of venous thrombosis, especially in atypical locations such as hepatic or cerebral veins. Diagnosis relies on high-sensitivity flow cytometry to detect GPI-anchored protein deficiency on granulocytes and RBCs; bone marrow examination may reveal concurrent aplastic anemia or myelodysplastic features. Eculizumab and newer complement inhibitors (e.g., ravulizumab, pegcetacoplan) have transformed PNH management, significantly reducing hemolysis, transfusion dependence, and thrombotic events—though lifelong therapy and monitoring remain essential.

China offers distinct advantages for PNH treatment: its leading hematology centers—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—host internationally trained specialists with extensive experience in rare hematologic disorders and early access to FDA/EMA-approved complement inhibitors. Advanced flow cytometry platforms, next-generation sequencing for clonal monitoring, and integrated thrombosis prevention protocols ensure precision care. Clinical outcomes align with global benchmarks: over 90% of treated patients achieve sustained hemolysis control and improved quality of life, with published case series demonstrating favorable safety profiles even in complex presentations. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising drug authenticity or clinical standards—eculizumab biosimilars and locally approved novel agents further enhance affordability. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital credentials, coordinating appointments with PNH-specialized hematologists, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and multilingual clinical liaison—all designed to reduce logistical uncertainty and prioritize therapeutic continuity.